Skip to main content

Advertisement

Table 2 Orally administered anti-diabetic drugs (OAD) and insulin at baseline and the end of the monitoring period

From: Intensification of insulin therapy in patients with type 2 diabetes: a retrospective, non- interventional cohort study of patients treated with insulin glargine or biphasic human insulin in daily clinical practice

  Control group Active group p-value
Start of the monitoring period n (%) or mean value ±  SD
Metformin 71 (44.7) 64 (45.1) 0.942
Sulfonylureas 15 (9.4) 14 (9.9) 0.901
Meglitinides (repaglinide/nateglinide) 0 (0.0) 0 (0.0) -
Thiazolidinedions 3 (1.9) 10 (7.0) 0.028
Alpha-glucosidase inhibitor 2 (1.3) 1 (0.7) 1.0
Other* 1 (0.6) 0 (0.0) 1.0
Biphasic human insulin (U/day) 47.84 ± 20.05 44.75 ± 19.85 0.18
Biphasic human insulin (U/kg/day) 0.61 ± 0.27 0.56 ± 0.25 0.13
End of the monitoring period n (%)
Metformin 63(39.6) 62 (43.7) 0.478
Sulfonylurea 2 (1.3) 18 (12.7) <0.001
Meglitinides (repaglinide/nateglinide) 0 (0.0) 6 (4.2) 0.009
Thiazolidinedions 1 (0.6) 7 (4.9) 0.021
Alpha-glucosidase inhibitor 1 (0.6) 1 (0.7) 1.0
Other* 1 (0.6) 2 (1.4) 0.604
Total insulin (glargine or biphasic plus prandial) dose (U/day) 50.89 ± 21.56 42.97 ± 21.53 <0.001
Total insulin (glargine or biphasic plus prandial) dose (U/kg/day) 0.65 ± 0.28 0.53 ± 0.26 <0.001
Change [%, 95% confidence intervals, (CI)] in the OAD and daily insulin dose between baseline and the end of the monitoring period
  %, 95% CI %, 95% CI  
Metformin -5.0 (-9.5, -0.4) -1.4 (-6.6, 3.8)  
p-value (baseline vs end) 0.033 0.593  
Sulfonylureas -8.1 (-12.9, 0.4) 2.8 (-3.9, 3.8)  
p-value (baseline vs end) 0.001 0.393  
Meglitinides (repaglinide/nateglinide) 0.0 4.2 (0.8, 7.6)  
p-value (baseline vs end) - 0.014  
Thiazolinidiones -1.3 (-3.0, 0.5) -2.1 (-5.2, 1.0)  
p-value (baseline vs end) 0.157 0.180  
Alpha-glusidase inhibitor 0.0 0.0  
p-value (baseline vs end) 0.317 -  
Other* 0.0 (-1.7, 1.7) 1.4 (-0.5, 3.4)  
p-value (baseline vs end) 1.0 0.157  
Total insulin (glargine or biphasic plus prandial) dose (U/day) 3.49 (2.16, 4.82) -1.78 (-5.25, -1.69)  
p-value (baseline vs end) <0.001 0.01  
Total insulin (glargine or biphasic plus prandial) dose (U/kg/day) 0.04 (0.02, 0.06) -0.02 (-0.07, -0.01)  
p-value (baseline vs end) <0.001 0.007  
  1. *Other includes dipeptidyl-peptidase 4 inhibitors or glucagon-like peptide 1 mimetics.